BUSINESS
Fortis saga: NCLT admits Shivinder's petition alleging financial misconduct, forgery against Malvinder
In the 43-page petition, Shivinder alleged his brother Malvinder and Godhwani for perpetrating “oppression and mismanagement” and sought removal of Malvinder from the board of RHC and restitution of funds diverted by the duo.
BUSINESS
Aurobindo Pharma acquires Sandoz's dermatology & oral solid biz in US for $900 million
The deal will position Aurobindo as the second-largest dermatology player and the second-largest generics company in the US by prescriptions.
BUSINESS
Is it too late for Shivinder Singh to absolve himself from the group’s troubles?
Shivinder Singh, the younger sibling, broke his silence on Tuesday accusing his brother Malvinder and family friend Sunil Godhwani for systemically undermining the interests of the group companies and their shareholders
BUSINESS
Competition Commission to investigate unfair pricing by private hospitals in Delhi
The Commission noted that huge profit margins are being earned by sale of products to the locked-in in-patients to the detriment of such patients.
BUSINESS
Fortis saga: Shivinder Singh moves NCLT against elder brother Malvinder
Shivinder said that he can no longer be party to activities in which transparency and ethics are continuously and consistently negated.
BUSINESS
J&J faulty hip implant case: Govt appoints 5-member central expert committee to determine compensation for patients
The five-member Central expert committee will review the reports of state level committees or applications submitted by affected patients based parameters such as degree of disability and patient suffering on account of monetary loss due to loss of wages and other losses. The base amount was fixed at Rs 20 lakh.
BUSINESS
India to unveil Charter of Patients' Rights soon
The charter, prepared by the National Human Rights Commission, lays down 17 basic rights of citizens
BUSINESS
E-pharmacies welcome govt draft rules, say compliance shouldn't be a problem
The draft notes e-pharmacies will have to pay Rs 50,000 to renew licenses and the premises from where e-pharmacies operate will be inspected every two years.
BUSINESS
J&J's faulty hip implant: Expert panel says gaps in follow-up care and compensation to patients
A 11-member expert committee was constituted in February 2017 under Dr Arun Agarwal to examine issues related to faulty ASR hip implants based on complaints made by some patients.
BUSINESS
J&J's faulty hip implant: Group of patients seeks expedited release of expert panel report
The patient group has written to health minister JP Nadda alleging that officials in the CDSCO and in the Ministry of Health and Family Welfare were sitting on the expert committee report without providing any reasons for not making it public.
BUSINESS
Indian drug makers see hike in Chinese raw material as an opportunity to produce locally
There are around 7,000 active pharmaceutical ingredient manufacturers in China, catering to around 80 percent of India drug makers’ raw material needs.
BUSINESS
Pharma weekly wrap: Singh bros put blame on former top executive Sunil Godhwani for group's financial woes
Godhwani was leading group's financial services arm Religare Enterprises as MD and CEO, was also in charge of the group's holding company, RHC Holding.
BUSINESS
WHO classifies bedaquiline as priority drug in multi-drug resistant TB treatment
WHO, however, warned that it does not have evidence on the safety and effectiveness of bedaquiline use beyond six months, as it was insufficient for review
BUSINESS
Government to launch Ayushman Bharat with public hospitals only, initially
Insurance companies are hoping to play a larger role in the health insurance scheme from 2019 onwards. Due to the proposed low rates, private hospitals have been reluctant to join
BUSINESS
Ayushman Bharat: States still in wait-and-watch mode
Sources told Moneycontrol that there could be a grand launch in states like Gujarat and Haryana tomorrow.
BUSINESS
Fortis Health posts Rs 52.8 crore Q1 loss; shareholders approve $1.1 bn deal with IHH
The deal now needs a go ahead from Competition Commission of India (CCI) to be consummated.
BUSINESS
No reason for pvt hospitals to sit out of path-breaking govt initiative: Ayushman Bharat CEO
“We want to make sure that rates are high enough so that we can attract the private sector, but at the same time they should not be so high that they make the scheme unsustainable,” Bhushan said.
BUSINESS
California verdict on Monsanto's Roundup could have India implications
The latest annual report of Monsanto’s India unit states that its brand Roundup maintains market leadership with sales of around Rs 185.66 crore, which is 28 percent of its net sales of Rs 667.44 crore in FY18
BUSINESS
In a battle over a Rs 250-cr product, Novartis is unwilling to yield an inch
Novartis' Diclofenac injection 75 mg/1 ml was recently banned at the behest of Indian drug regulator after complaints by a little known Ahmedabad-based company, which had a competing product
BUSINESS
The curious case of Oxytocin retail ban by government
The government said the curbs on oxytocin is to restrict the abuse of the hormonal drug by dairy industry on animals.
BUSINESS
Torrent Pharma Q1 profit drops 13% to Rs 162 cr on higher amortisation, finance costs
Torrent Pharma bought domestic formulation business of Unichem Laboratories Rs 3600 crore in December 2017.
BUSINESS
Healthtech disruption: An AI a day helps the doctor a long way
One area that’s ripe for disruption is diagnostics – as successful diagnosis depends on recognition of patterns, mostly visual. That is where AI has an edge compared to humans.
BUSINESS
Delhi HC asks Singh brothers to personally appear for proceedings in Daiichi case
The summons were issued as the court wasn't satisfied with the information provided by Singh brothers on the status of their assets under possession.
BUSINESS
Ayushman Bharat: Insurance companies left in lurch as states opt for trust-based models
In a trust-based model, each state will form its own trust to manage the scheme and claims will be paid from a corpus created from central and state government contributions
